You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
現代製藥(600420.SH)苯磺酸氨氯地平片(5mg)通過一致性評價
格隆匯 08-22 20:35

格隆匯8月22日丨現代製藥(600420.SH)公佈,近日,公司全資子公司國藥集團容生製藥有限公司(“國藥容生”)通過國家藥品監督管理局藥品審評中心(“CDE”)網站獲悉,國藥容生的苯磺酸氨氯地平片(5mg)已通過仿製藥質量和療效一致性評價。

苯磺酸氨氯地平片適用於高血壓、冠心病的對症治療,原研廠家為輝瑞製藥有限公司(“輝瑞製藥”),藥品商品名為“絡活喜”。根據PDB統計數據,該藥品2018年度全球銷售額為64.99億美元,其中輝瑞製藥的絡活喜銷售收入10.24億美元;國內樣本醫院用藥2018年度銷售額為人民幣7.79億元。

CDE網站顯示,目前苯磺酸氨氯地平片(5mg)通過一致性評價的還有江蘇黃河藥業股份有限公司、華潤賽科藥業有限責任公司、辰欣藥業股份有限公司、浙江京新藥業股份有限公司等其他9家公司。

國藥容生苯磺酸氨氯地平片(5mg)2018年度銷售收入約為1172萬元。截至目前,國藥容生開展苯磺酸氨氯地平片(5mg)一致性評價累計投入費用約750萬元(未經審計)。

子公司國藥容生苯磺酸氨氯地平片(5mg)通過一致性評價,有利於擴大該藥品的市場份額,提升市場競爭力。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account